VolitionRx

About:

VolitionRx develops easy to use blood-based cancer tests to accurately diagnose a range of cancers.

Website: https://volition.com

Twitter/X: VolitionRx

Top Investors: WE International, Namur Invest

Description:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid which is an indication that disease is present. As cancer screening programs become more and more widespread, its products aim to help to diagnose a range of cancers quickly, simply, accurately, and cost-effectively. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and worldwide.

Total Funding Amount:

$87.8M

Estimated Revenue Range:

$500M to $1B

Headquarters Location:

Singapore, Central Region, Singapore

Founded Date:

2010-01-01

Contact Email:

info(AT)volitionrx.com

Founders:

Andreas Ladurner, Martin Faulkes

Number of Employees:

101-250

Last Funding Date:

2024-08-09

IPO Status:

Public

Industries:

© 2025 bioDAO.ai